I Took Adderall Every Day for a Year: What It Did to My Brain & Soul
Big Pharma: The Greatest Business America Ever Built · Episode 1 of 6 ADHD Medications
Rxan Smith: Uncomfortable · Homepage | RxanSmithMedia.com | Debt Clock
Big Pharma Series / ADHD Medications
Adderall, Ritalin, & Speed… Oh My
America put millions of kids on Schedule II amphetamines, reassured parents despite limited long-term data, collected five decades of patients who now can’t function without the pills, and called it medicine. The drug companies called it a growth market. Congress called it Thursday.
buymeacoffee.com/rxansmith · paypal.me/phireballsports
Name a legal product that requires a federal DEA license to prescribe, often cannot be phoned into a pharmacy, and usually must be picked up in person with government ID. It carries a Black Box warning for potential abuse. Yet, it is routinely prescribed to children as young as six after a fifteen-minute office visit. This industry generates nineteen billion dollars annually. It sits in the same DEA schedule as cocaine and morphine.
Welcome to the ADHD medication system. Make yourself comfortable. A lot of people can’t anymore without it.
◆ ◆ ◆
Part One: What We’re Actually Talking About
The Chemistry of Compliance
Let’s establish the pharmacology, because this is where the conversation usually dies before it starts. Adderall is amphetamine salts. Ritalin is methylphenidate. Different compounds, similar outcome: increased dopamine and norepinephrine activity, improving focus and task execution in the short term. These drugs are effective; that isn’t the debate. The question is what happens after decades of continuous use—and that’s where the evidence gets thinner than the confidence. When you modulate brain chemistry daily for thirty years, you aren’t just “fixing” a problem; you are managing an ongoing biological adaptation.
The pharmaceutical industry spent considerable energy framing these facts as “glasses for the brain.” This analogy is so pervasive, so casually deployed in doctors’ offices and school counselors’ meetings, that most people have stopped asking the obvious follow-up: what is your evidence for that, and does it hold up after forty years of continuous use?
There is no blood test, no brain scan, no biomarker of any kind that can objectively confirm an ADHD diagnosis. The condition is real. The diagnostic tool is a symptom checklist evaluated in a fifteen-minute pediatrician appointment 90 percent of the time. The Uncomfortable Position
Part Two: The Diagnosis Problem
A Disease That Fails Its Own Audit
Try to name another condition for which American medicine routinely prescribes a federally controlled stimulant for decades without a single objective confirmatory test. You cannot. ADHD diagnosis lives entirely in the DSM-5, a document that defines the disorder not by neurological evidence but by behavioral thresholds. And when subjective systems scale quickly, error scales with them.
The *relative age effect is the most damning illustration of how the diagnostic process works. Children born in the final months of the calendar year, who are developmentally younger than their classmates, are diagnosed and medicated at significantly higher rates. We aren’t just diagnosing behavior. Sometimes, we’re diagnosing timing.
Part Three: What Gets Skipped
The Therapy Gap
In much of Europe, behavioral therapy is the first step. In the United States, medication often is. This isn’t because therapy doesn’t work; it’s because therapy is slower, harder to scale, and reimbursed poorly by insurance. Medication is fast. And American healthcare rewards speed. A prescription takes four minutes; a pharmacy handles the rest. The drug companies understood this long ago and built their market strategies around the path of least resistance.
Healthcare Cost Control (Ep. 2)
Why the system favors the billable procedure over the durable outcom
This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.
buymeacoffee.com/rxansmith · paypal.me/phireballsports
◆ ◆ ◆
Part Four: The Long-Term Question
The Patients Who’ve Been on This for Forty Years
Over time, the brain adapts to stimulant use. This adaptation includes tolerance and, for many, withdrawal symptoms when the drug is removed. Many long-term users report profound difficulty functioning without the medication—a state the clinical establishment calls “untreated ADHD.” Critics ask whether, in some cases, it’s also the result of long-term pharmacological adaptation. That question remains unresolved in the literature. What isn’t unresolved is the outcome: patients who don’t easily leave the system.
That is not an accident of science. It is an outcome the market selected for
The pharmaceutical industry built a product that works well enough in the short term to generate referrals, creates enough dependency in the long term to ensure retention, and is covered by enough diagnostic ambiguity that the liability never quite lands where it belongs.— The Structural Argument
Part Five: Vyvanse, or How to Sell the Same Drug Twice
The Rebrand Strategy
Vyvanse works because your body converts it into dextroamphetamine—the same core stimulant used for nearly a century. Takeda protected this “prodrug” design with a patent that generated billions while the molecule inside was essentially off-patent. They expanded the indication to Binge Eating Disorder just as the ADHD patent cliff approached. It’s a masterclass in market strategy, ensuring maximum revenue until the very day generics are legally allowed to compete. That is not corruption. That is the system operating exactly as designed.
◆ ◆ ◆
The Bottom Line
What We’ve Actually Built Here
The American ADHD medication industry discovered that a disorder with no objective test, a diagnostic process that rewards speed, and a medication that creates long-term neurological dependency was, financially speaking, nearly perfect. Recession-proof. Retention-guaranteed.
The disorder is real. The medication helps many people. Both of those facts can coexist with the structural critique: when you find a medical condition that generates billions, creates a patient population that cannot easily discontinue treatment, and carries enough diagnostic ambiguity that liability never quite consolidates into accountability, you have found a business model wearing a white coat.
Stop calling it a mental health crisis when what you mean is a system that pathologized childhood behavior and responded with Schedule II medication. At some point, the dog ate so much homework that the dog became the homework.
I’m not here to tell you Adderall doesn’t work. It works. The argument is that a system which works well enough in the short term to generate referrals, but creates enough dependency in the long term to ensure retention, is a scandal. We don’t consider that a feature. Except in American healthcare, where we consider it a revenue stream
The access exists. The effective care often doesn’t — a gap that runs through the entire system
A fifteen-minute checklist to start a forty-year pharmaceutical relationship is not medicine. It’s a sales funnel in a stethoscope. The UK looked at this system and declined. Germany looked at it and declined. America looked at it and said: nineteen billion dollars a year sounds about right.
See you next week for opiates. Bring your proof of ID.
— Rxan Smith · Rxan Smith: Uncomfortable · April 2026
Next episode: Opiates. Buckle up.
buymeacoffee.com/rxansmith · paypal.me/phireballsports
A system that creates long-term dependency while calling it treatment deserves its own conversation
Big Pharma Miniseries · All Episodes
▶ Episode 1: Adderall, Ritalin, & Speed, Oh My: ADHD Meds (YOU’RE HERE)
○ Episode 2: The Pill That Ate America — Opiates [Coming Soon]
○ Episode 3: Calm Down or Stay Numb — Benzos & Antidepressants [Coming Soon]
○ Episode 4: Performance, Vanity, and the Weight of Profit — Sex, Hair & Weight Drugs [Coming Soon]
○ Episode 5: The Jab Economy — Vaccines & Elder Medications [Coming Soon]
○ Episode 6: The Whole Machine — Big Pharma & the Five Industries That Own “Healthcare” [Coming Soon]
Support Rxan Smith: Uncomfortable
buymeacoffee.com/rxansmith · paypal.me/phireballsports
$5 — You read it and it made you uncomfortable. Good.
$10 — You shared it because you knew someone needed to see it.
$25 — You’re the person in the room who actually says the thing.
$50 — You’ve been trying to explain this to people for years.
$100 — You want this work to keep existing, independently, for as long as it takes.
$250 — You understand that no sponsors means no compromises.
$500 — RXAN OWES ME.
buymeacoffee.com/rxansmith · paypal.me/phireballsports
Contact: uncomfortablerxansmith@gmail.com